UC researchers find protein that mediates formation of HER2-driven breast cancer

(University of Cincinnati Academic Health Center) Researchers at the University of Cincinnati College of Medicine have identified for the first time that the estrogen receptor-binding protein MED1 is a critical mediator of HER2-driven breast cancer, identifying it as a potential therapeutic target.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Conclusions: In our experience, the use of odx was concordant with published recommendations and had a positive cost impact. PMID: 30111977 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Conclusions: Study results indicate that, for patients and caregivers, pd health states are associated with a deterioration of qol and utility and a decrease in productivity in both 1l and ≥2l. PMID: 30111973 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Basal/human epidermal growth factor receptor (HER)2-positive (HER2+) breast cancer is resistant to monoclonal antibody (herceptin) treatment. There are currently only three basal/HER2+ breast cancer cell lines...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
SummaryIn the areas of chemotherapy, targeted therapy and immunotherapy, several interesting and clinically relevant data were presented at the 2017 San Antonio Breast Cancer Symposium (SABCS). This short review focuses on dose-dense and/or sequential administration of adjuvant chemotherapy, provides an update on targeted therapies for HER2-positive and triple-negative breast cancer and summarizes new results in the field of immunotherapy.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
AbstractOverexpression of human epidermal growth factor receptor 2 (HER2) protein in association withHER2 gene amplification is found in 7 –34% of gastric cancers. In breast cancer, HER2 overexpression is a prognostic factor in advanced cases and is associated with tumor progression in ductal carcinoma in situ. However, the biological and clinical significance of HER2 status in early gastric cancer is unknown. Here, we aimed to exami ne the correlation betweenHER2 gene amplification and tumor progression in early gastric cancer. The HER2 status was evaluated in 149 lesions from 141 consecutive patients with early gas...
Source: Virchows Archiv - Category: Pathology Source Type: research
Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2/Neu Negative;   Stage IV Breast Cancer AJCC v6 and v7 Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Breast Cancer;   HER2+ Breast Cancer Interventions:   Biological: VRP-HER2;   Biological: Pembrolizumab Sponsors:   Herbert Lyerly;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2/Neu Negative;   Stage IV Breast Cancer AJCC v6 and v7 Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Breast Cancer;   HER2+ Breast Cancer Interventions:   Biological: VRP-HER2;   Biological: Pembrolizumab Sponsors:   Herbert Lyerly;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2/Neu Negative;   Stage IV Breast Cancer AJCC v6 and v7 Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academia | Breast Cancer | Cancer | Cancer & Oncology | HER2